Matthias Mann (Univ. of Copenhagen)

Matthias Mann (Univ. of Copenhagen)

Butler Seminar Series

Event Date/Location

January 26, 2018 -
12:00 pm to 1:00 pm
Thomas Laboratory 003


  • Matthias Mann

    University of Copenhagen

    Matthias Mann studied physics and mathematics at Göttingen University in Germany and obtained his Ph.D. in chemical engineering at Yale University. Here he was decisively involved in the development of electrospray ionization, which has become a key technology of the life sciences. As a post-doctoral fellow and later as a professor for bioinformatics at the University of Southern Denmark in Odense, he developed, amongst others techniques, the first bioinformatic search algorithms for peptide fragmentation data and SILAC, a new method of quantitative proteomics and a breakthrough in the mapping of protein interactions.

    In 2005, Matthias Mann took up a director position at the Max-Planck Institute of Biochemistry in Munich. Here his group continues to address a wide range of biological questions using proteomic technology, as well as to develop this technology. The group is also heavily involved in providing proteomic methods and tools to the community. Most importantly in this regard, they have provided the MaxQuant suite of computational proteomics algorithms; this software promises to significantly advance the state of the field. More recently his group used the SILAC technology in conjunction with MaxQuant to describe the first comprehensive identification and quantification of a proteome. (

    In 2009 Dr. Mann was additionally appointed director of the proteomics program of the Novo Nordisk Foundation Center for Protein Research in Copenhagen.

    Matthias Mann has authored and co-authored more than 500 publications with a total citation count of more than 50,000, making him one of the most highly cited researchers worldwide, has been elected to membership of the European Molecular Biology Organization, Royal Danish Academy of Arts and Sciences and the Leopoldina German National Academy of Sciences as well as to a visiting professorship at Harvard Medical School. He has received two honorary degrees from Utrecht University and the University of Dundee, respectively.

    In 2012 he was awarded the Leibniz Prize from the German Research Foundation, the Ernst Schering Prize, and the Louis-Jeantet Foundation Prize for Medicine and the Körber European Science Prize.


Proteomics and phosphoproteomics for cell signaling and clinical applications

Mass spectrometry (MS)-based proteomics has become a powerful technology to study nearly the entire collection of proteins in cells and tissues. Here I describe the latest workflow developments in our group and their application to a variety of cell biological and biomedical problems. These include the analysis of formalin-fixed, paraffin embedded tissues from just a few thousand cells in the context of treatment sensitivity or resistance in ovarian cancer. In this study, we discovered a biomarker candidate, which we then explored using different layers of proteomics – including interaction proteomics, phosphoproteomics and immunopeptidomics – as well as functional and imaging assays.  

Using a recently developed and highly streamlined phosphor-peptide enrichment protocol, we have followed insulin signaling in vivo with high time resolution and at a depth of more than 10,000 quantified phosphosites (Humphrey et al. Nat. Biotech. 2015). We have now applied this technology to in vivo study of the circadian rhythm as well as opioid signaling in the mouse brain.

Finally, in an effort to directly apply proteomics in the clinic, we have developed a robust technology termed Plasma Proteome Profiling (Geyer et al. Cell Systems, 2016, Geyer et al. MSB 2017), which holds great promise for the unbiased and minimally invasive phenotyping of humans in health and disease.  


Free and open to the university community and the public.


Ileana Cristea and Martin Wuhr